Pharming Group opens trading
Sijmen de Vries, CEO of the Euronext listed Pharming Group (ticker symbol: PHARM) sounds the gong at the Amsterdam exchange. Pharming Group is celebrating its first half year of net profitability and the opening of its regional non-deal retail investor roadshow.
The company is now the first and only Dutch biotech company to commercialize a self- developed product, RUCONEST®, in North America. This therapy is approved for acute attacks of Hereditary Angio-Edema (HAE), instant and sometimes life-threatening swellings in various body parts including the hands, feet, face and airway. This as result of the closing of an agreement with its US partner Valeant Pharmaceuticals to buy back the marketing rights of its own medicine in the US, Canada and Mexico. In addition, following an amendment of its agreement with its EU partner Sobi, Pharming also takes on commercialization of RUCONEST in most of Western- Europe.
For more information: www.pharming.com